Tin tức & Cập nhật

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023 bởiJairia Dela Cruz

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
11 Oct 2023
ALA-PDT on par with minocycline for moderate-to-severe rosacea
ALA-PDT on par with minocycline for moderate-to-severe rosacea
08 Oct 2023

Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.

ALA-PDT on par with minocycline for moderate-to-severe rosacea
08 Oct 2023
ICI-related adverse events tied to longer survival in metastatic NSCLC
ICI-related adverse events tied to longer survival in metastatic NSCLC
08 Oct 2023 bởiStephen Padilla

Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.

ICI-related adverse events tied to longer survival in metastatic NSCLC
08 Oct 2023